CA2718580A1 - Methods for identifying kinase modulators - Google Patents

Methods for identifying kinase modulators Download PDF

Info

Publication number
CA2718580A1
CA2718580A1 CA2718580A CA2718580A CA2718580A1 CA 2718580 A1 CA2718580 A1 CA 2718580A1 CA 2718580 A CA2718580 A CA 2718580A CA 2718580 A CA2718580 A CA 2718580A CA 2718580 A1 CA2718580 A1 CA 2718580A1
Authority
CA
Canada
Prior art keywords
polypeptide
lrrk2
compound
erm family
modulates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2718580A
Other languages
French (fr)
Inventor
Dario Alessi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of CA2718580A1 publication Critical patent/CA2718580A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method for identifying a compound expected to be useful in modulating a LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates the protein kinase activity of a LRRK2 polypep-tide on a substrate Ezrin/Radixin/moesin (ERM) family polypeptide and (2) selecting a compound which modulates the LRRK2 polypeptide protein kinase activity. Such a compound may be useful in treating Parkinson's Disease or Parkinsonism. A
catalyti-cally active fragment of LRRK2 is identified, requiring the GTPase, COR and kinase domains as well as the WD_40-like motif and C-terminal tail.

Claims (37)

1. A method for identifying a compound expected to be useful in modulating protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates the protein kinase activity of a LRRK2 polypeptide on a substrate Ezrin/Radixin/Moesin (ERM) family polypeptide and (2) selecting a compound which modulates the said LRRK2 polypeptide protein kinase activity.
2. A method for identifying a compound expected to be useful in modulating, for example inhibiting, the phosphorylation of an ERM family polypeptide in a cell, the method comprising the steps of (1) determining whether a test compound modulates, for example inhibits, the protein kinase activity of a LRRK2 polypeptide, and (2) selecting a compound which modulates, for example inhibits, the protein kinase activity of the LRRK2 polypeptide.
3. A method for identifying a method for identifying a compound expected to be useful in treating or preventing Parkinson's Disease (PD) or Parkinsonism or other neurodegenerative condition, the method comprising the steps of (1) determining whether a test compound modulates, for example inhibits, the phosphorylation of an ERM family (for example moesin) polypeptide, and (2) selecting a compound which modulates, for example inhibits, the phosphorylation of the ERM family (for example moesin) polypeptide.
4. The method of claim 3 comprising the steps of (1) determining whether a test compound modulates, for example inhibits, the phosphorylation of an ERM family (for example moesin) polypeptide by an LRRK2 polypeptide, and (2) selecting a compound which modulates, for example inhibits, the phosphorylation of the ERM

family (for example moesin) polypeptide by the LRRK2 polypeptide.
5. The method of any one of claims 1 to 4 wherein the LRRK2 polypeptide is wild type human LRRK2 or a fragment thereof, or a fusion either thereof.
6. The method of claim 5 wherein the fragment comprises at least residues 1326-of wild type human LRRK2.
7. The method of any one of claims 1 to 5 wherein the LRRK2 polypeptide is human LRRK2 having a naturally occurring mutation of wild type human LRRK2; or a fragment thereof; or a fusion either thereof.
8. The method of claim 7 wherein the naturally occurring mutation of human LRRK2 is a mutation associated with Parkinson's Disease (Pb).
9. The method of claim 7 or 8 wherein the mutation, using the numbering of wild type human LRRK2, is G2019S.
10. The method of claim 7 or 8 wherein the mutation, using the numbering of wild type human LRRK2, is R1441C, R1441G, Y1699C, R1914H, I2012T, 12020T, T2356I, G2385R, K544E, P755L, R793M, Q930R, S973N, R1067Q, S1096C, I1122V, S1228T, I1371V, R1441H, A1442P, R1514Q, M1869T or G2019S.
11. The method of any one of claims 7 to 10 wherein the fragment corresponds to at least residues 1326-2527 of human LRRK2.
12. The method of any one of the preceding claims wherein the LRRK2 polypeptide is a GST fusion polypeptide.
13. The method of claim 12 wherein the LRRK2 polypeptide is CST-LRRK2[1326-2527, G2019S].
14. The method of any one of the preceding claims wherein the LRRK2 polypeptide and/or ERM family polypeptide is recombinant.
15. The method of any one of the preceding claims wherein the ERM family polypeptide is a fragment derivable from an ERM family polypeptide, for example moesin, radixin or ezrin, which encompasses the residue corresponding to Thr558 residue of moesin and at least part of the surrounding sequence which includes this residue, for example at least the 2, 3, 4, 5, 6 or 7 residues C-terminal and N-terminal of this residue, for example the polypeptide RLGRDKYKTLRQIRQ or RLGRDKYKTLRQIRQGNTKQR; or a polypeptide of less than 100, 80, 60, 50, 40, 30, 25, 20, 19, 18, 17 or 16 amino acids, comprising the amino acid sequence RLGRDKYK(T/S)LRQIRQ or RLGRDKYK(T/S)LRQIRQGNTKQR, each with no or up to one, two, three, four, five, six, seven, eight, nine or ten conservative or non-conservative substitutions of residues other than the T/S residue.
16. A purified preparation or kit of parts comprising a LRRK2 polypeptide or polynucleotide and an ERM family polypeptide or polynucleotide.
17. The preparation or kit of claim 16 comprising a recombinant LRRK2 polynucleotide.
18. The preparation or kit of parts of claim 16 or 17 comprising a recombinant ERM family polynucleotide.
19. A recombinant cell capable of expressing a LRRK2 polypeptide and an ERM
family polypeptide.
20. The recombinant cell of claim 19 comprising a recombinant LRRK2 polynucleotide and a recombinant ERM family polynucleotide.
21. A recombinant cell according to claim 19 comprising a LRRK2 polypeptide and ERM
family polypeptide.
22. A method for making a preparation according to any one of claims 16 to 18 comprising the step of purifying the preparation from a cell according to any one of claims 19 to 21.
23. A preparation obtainable by the method of claim 22.
24. A truncated LRRK2 polypeptide of less than 2000 amino acids having protein kinase activity on a substrate ERM family polypeptide, comprising at least the GTPase domain, COR domain, kinase domain, WD40-like motif and C-terminal tail residues of wild type human LRRK2 or a variant or naturally occurring mutant thereof.
25. The truncated LRRK2 polypeptide of claim 24 comprising at least residues of wild type human LRRK2 or a variant or naturally occurring mutant thereof.
26. LRRK2 polypeptide GST-LRRK2[1326-2527, G2019S] or GST-LRRK2[1326-2527]
27. An substrate polypeptide which is a fragment derivable from an ERM family polypeptide, for example moesin, radixin or ezrin, which encompasses the residue corresponding to Thr558 residue of moesin and at least part of the surrounding sequence which includes this residue, for example at least the 2, 3, 4, 5, 6 or 7 residues C-terminal and N-terminal of this residue, for example the polypeptide RLGRDKYKTLRQIRQ or RLGRDKYKTLRQIRQGNTKQR; or a polypeptide of less than 100, 80, 60, 50, 40, 30, 25, 20, 19, 18, 17 or 16 amino acids, comprising the amino acid sequence RLGRDKYK(T/S)LRQIRQ or RLGRDKYK(T/S)LRQIRQGNTKQR each with no or up to one, two, three, four, five, six, seven, eight, nine or ten conservative or non-conservative substitutions of residues other than the T/S residue.
28. A polynucleotide encoding a truncated LRRK2 polypeptide according to any one of claims 24 to 26.
29. A polynucleotide encoding the substrate polypeptide of claim 28.
30. A method of phosphorylating an ERM family polypeptide wherein the ERM
family polypeptide is phosphorylated by an LRRK2 polypeptide.
31. Use of an LRRK2 polypeptide in a method of phosphorylating an ERM family polypeptide.
32. The method of claim 30 wherein the ERM family polypeptide is phosphorylated on the threonine residue corresponding to Thr558 of full length human moesin.
33. The method of any one of claims 1 to 15 comprising the step of assessing whether the compound modulates ERM family polypeptide phosphorylation in a whole cell, tissue or organism; or characteristics of Parkinsonism or Parkinson's Disease in an organism and a compound that modulates the activity or disease characteristics is selected.
34. The method of claim 33 further comprising the step of assessing whether the compound modulates the activity of an ERM family polypeptide in the whole cell, tissue or organism, and a compound that modulates the activity is selected.
35. The method of any one of claims 1 to 15, 33 or 34 further comprising the step of synthesising, purifying and/or formulating the selected compound.
36. A method for preparing a compound which modulates the activity of a LRRK2 polypeptide or phosphorylation of an ERM family polypeptide, the method comprising 1) performing a method according to any one of claims 1 to 15, 33 or 34 and 2) synthesising, purifying and/or formulating the selected compound.
37. A method of characterising an LRKK2 mutant, for example an LRRK2 mutant found in a patient with Parkinson's Disease, the method comprising the step of assessing the ability of the LRKK2 mutant to phosphorylate a substrate ERM family polypeptide.
CA2718580A 2007-04-05 2008-04-07 Methods for identifying kinase modulators Abandoned CA2718580A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91024207P 2007-04-05 2007-04-05
US60/910,242 2007-04-05
GBGB0706709.3A GB0706709D0 (en) 2007-04-05 2007-04-05 Methods
GB0706709.3 2007-04-05
PCT/GB2008/001211 WO2008122789A2 (en) 2007-04-05 2008-04-07 Methods for modulating lrrk2

Publications (1)

Publication Number Publication Date
CA2718580A1 true CA2718580A1 (en) 2008-10-16

Family

ID=38090954

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2718580A Abandoned CA2718580A1 (en) 2007-04-05 2008-04-07 Methods for identifying kinase modulators

Country Status (8)

Country Link
US (1) US7947468B2 (en)
EP (1) EP2132326B1 (en)
JP (1) JP2010523101A (en)
CN (1) CN101688234A (en)
CA (1) CA2718580A1 (en)
DK (1) DK2132326T3 (en)
GB (1) GB0706709D0 (en)
WO (1) WO2008122789A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206942B2 (en) 2007-04-05 2012-06-26 Medical Research Council Methods of identifying LRRK2 inhibitors
GB0706709D0 (en) 2007-04-05 2007-05-16 Medical Res Council Methods
GB2463656B (en) * 2008-09-18 2010-10-13 Medical Res Council Substrate of LRRK2 and methods of assessing LRRK2 activity
JP2012254937A (en) * 2009-09-11 2012-12-27 Kyushu Univ New matrix peptide of rho-kinase
US9127077B2 (en) 2009-09-23 2015-09-08 L'universite Paris Descartes Polypeptides and nucleic acids for treating ErbB2-dependent cancers
US8367349B2 (en) 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2
KR101571940B1 (en) 2010-10-08 2015-11-25 상하이 켁신 바이오테크 씨오., 엘티디. Moesin fragments associated with immune thrombocytopenia
KR101631740B1 (en) 2010-10-08 2016-06-17 상하이 켁신 바이오테크 씨오., 엘티디. Diagnostic and therapeutic uses of moesin fragments
JP5868409B2 (en) * 2010-10-08 2016-02-24 シャンハイ クーシン バイオテック カンパニー，リミテッド Moesin fragment and uses thereof
EP2624855B1 (en) * 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Moesin fragments associated with aplastic anemia
EP2624854B1 (en) * 2010-10-08 2016-08-03 Shanghai Kexin Biotech Co., Ltd Moesin inhibitors and uses thereof
MX2013005801A (en) * 2010-11-30 2013-07-17 Genentech Inc Assays and biomarkers for lrrk2.
SG11201408044QA (en) 2012-06-29 2015-01-29 Pfizer NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
WO2015176010A1 (en) 2014-05-15 2015-11-19 The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services Treatment or prevention of an intestinal disease or disorder
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
US20180179594A1 (en) * 2016-10-31 2018-06-28 Parkinson's Institute Multiple system atrophy and the treatment thereof
CN108709997B (en) * 2018-05-28 2020-09-18 中国林业科学研究院林业研究所 Substrate search method for LRR receptor kinase
CN112843067B (en) * 2019-11-26 2023-01-06 兰州大学 Human LRRK2 protein small-molecule inhibitor and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166222A1 (en) * 2002-01-02 2003-09-04 Millennium Pharmaceuticals, Inc. 39267, human kinase family members and uses therefor
US20040265849A1 (en) * 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
JP2006174701A (en) * 2003-02-24 2006-07-06 Research Association For Biotechnology New protein and dna encoding the same
JP2009529860A (en) 2006-03-14 2009-08-27 セルゾーム・アクチェンゲゼルシャフト Method for identification of molecules with which LRRK2 interacts and purification of LRRK2
WO2008091799A2 (en) 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
GB0706709D0 (en) 2007-04-05 2007-05-16 Medical Res Council Methods

Also Published As

Publication number Publication date
GB0706709D0 (en) 2007-05-16
WO2008122789A2 (en) 2008-10-16
EP2132326B1 (en) 2012-10-31
DK2132326T3 (en) 2012-12-17
CN101688234A (en) 2010-03-31
US7947468B2 (en) 2011-05-24
US20090142784A1 (en) 2009-06-04
EP2132326A2 (en) 2009-12-16
WO2008122789A3 (en) 2008-12-04
JP2010523101A (en) 2010-07-15

Similar Documents

Publication Publication Date Title
CA2718580A1 (en) Methods for identifying kinase modulators
Sánchez et al. Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function
Winder et al. Regulation of smooth muscle actin—myosin interaction and force by calponin
Ingley et al. Pleckstrin homology (PH) domains in signal transducton
LeWinter et al. Cardiac titin: structure, functions and role in disease
SMALL et al. The cytoskeleton of the vertebrate smooth muscle cell
Correas et al. Microtubule-associated protein tau is phosphorylated by protein kinase C on its tubulin binding domain.
Imahori et al. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease
Manning et al. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling
AU2003234186B2 (en) Peptide inhibitors of protein kinase C Gamma for pain management
Elghazi et al. Regulation of β‐cell mass and function by the Akt/protein kinase B signalling pathway
Breton et al. Two novel intrinsic annexins accumulate in wheat membranes in response to low temperature
James et al. Signaling and myosin-binding protein C
Heierhorst et al. Autophosphorylation of molluscan twitchin and interaction of its kinase domain with calcium/calmodulin.
Lun et al. Probing muscle ankyrin‐repeat protein (MARP) structure and function
Shen Protein kinases linked to the pathogenesis of Parkinson's disease
Meijer et al. Tyrosine phosphorylation of Munc18‐1 inhibits synaptic transmission by preventing SNARE assembly
KR20130113962A (en) Neuregulin isoforms, neuregulin polypeptides and uses thereof
Young et al. LNX1 is a perisynaptic Schwann cell specific E3 ubiquitin ligase that interacts with ErbB2
CN106456700B (en) Novel targets for the treatment and prevention of diabetes
Adaikkan et al. The role of protein phosphorylation in the gustatory cortex and amygdala during taste learning
Katoh et al. Identification and characterization of human FNBP3 gene in silico
Lim et al. Genome protection by the 9-1-1 complex subunit HUS1 requires clamp formation, DNA contacts, and ATR signaling-independent effector functions
Kwon et al. The role of the p35/cdk5 kinase in cortical development
Noshita et al. Effect of nicotine on neuronal dysfunction induced by intracerebroventricular infusion of amyloid-ß peptide in rats

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150209